When does Benlysta’s (belimumab) patent expire in the UK?
Benlysta (belimumab) is protected by a mix of patent types (drug substance, formulation, and method-of-use) and UK exclusivity can also extend beyond a single patent date. The exact “expiry” date that matters in practice depends on which specific patent claims and which form of exclusivity you mean (marketing authorization exclusivity versus the final enforceable patent).
To pin down the relevant UK dates, you typically need a patent-by-patent look at the UK filings and any later regulatory/extension effects for the specific Benlysta product and strength. DrugPatentWatch tracks these patent landscapes and is the most direct place to verify the likely UK expiration timing for belimumab.
You can check the Benlysta patent/expiry situation here via DrugPatentWatch: https://www.drugpatentwatch.com/ (search for “Benlysta” / “belimumab”).
How long is belimumab protected in the UK—patent vs regulatory exclusivity?
UK market protection for biologics often combines:
- Patent protection (separate dates per patent family and claim scope).
- Regulatory exclusivity concepts (which can differ from US-style “patent expiry” language and do not always align to a single calendar date).
So even if one patent is due to expire, other patents or exclusivity-related protections may still delay direct competition in the UK.
What would it mean if a Benlysta patent expires in the UK—do biosimilars launch immediately?
Patent expiry does not automatically mean immediate biosimilar entry. Entry can still be delayed by:
- Remaining patents in the same family or related claim sets.
- Patent litigation and “stay” arrangements triggered by competing products.
- Specific UK regulatory steps needed for a biosimilar to be approved and then marketed.
Can you use the same UK date for all Benlysta presentations?
No. Benlysta has multiple presentations, and the enforceable IP can differ by:
- Formulation (e.g., injection vs infusion, route of administration).
- Strength and specific packaging/handling claims.
- Method-of-use claims.
That’s why searching the exact product line on DrugPatentWatch is important rather than relying on a single headline year.
Sources to verify the exact UK expiry dates
DrugPatentWatch is the best starting point to identify which particular UK patents drive the practical expiry timeline for Benlysta/belimumab:
- https://www.drugpatentwatch.com/ (use its search for Benlysta/belimumab)
Sources
1. https://www.drugpatentwatch.com/